Please check your internet connection and try again.
## Calcium Acetate
### Overview
Calcium acetate is a phosphate binder used to control hyperphosphatemia in patients with chronic kidney disease (CKD). It binds to dietary phosphate in the gastrointestinal tract, forming an insoluble calcium phosphate precipitate that is then excreted.
### Primary Indications
* Hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis.
### Adult Dosing
* **Starting Dose:** 667 mg (equivalent to 169 mg elemental calcium) with each meal.
* **Titration:** Dosage should be individualized based on serum phosphate levels. The goal is to maintain serum phosphate below 6 mg/dL.
* **Maximum Dose:** While not definitively established, doses up to 10-12 grams per day have been used. However, higher doses increase the risk of hypercalcemia. It is crucial to monitor calcium and phosphate levels closely during dose titration.
### Pediatric Dosing
* Dosing in pediatric patients is not well-established and should be guided by expert consultation and close monitoring of serum calcium and phosphate levels. Some sources suggest starting doses of 10-20 mg/kg/day divided into 3 doses with meals, but this requires careful adjustment.
### Dose Adjustments
* **Renal Impairment:** Calcium acetate is primarily used in patients with ESRD. In patients with CKD not on dialysis, dose may need adjustment based on serum calcium and phosphate levels to avoid hypercalcemia and adynamic bone disease.
* **Hepatic Impairment:** No specific dose adjustments are required.
### Contraindications
* Hypercalcemia
* Hypersensitivity to calcium acetate or any component of the formulation
* Concerns about phosphate depletion
### Adverse Effects
* **Common:** Hypercalcemia (most significant concern), constipation, nausea, vomiting.
* **Serious:** Vascular calcification, cardiovascular events, hypophosphatemia, milk-alkali syndrome (especially with co-administration of calcium-rich antacids or supplements).
### Key Drug Interactions
* **Tetracyclines and Fluoroquinolones:** Calcium acetate can decrease the absorption of these antibiotics. Separate administration by at least 2 hours.
* **Thyroid Hormones:** Calcium acetate can decrease the absorption of levothyroxine. Separate administration by at least 4 hours.
* **Antacids:** Concurrent use of other calcium-containing products can increase the risk of hypercalcemia.
* **Vitamin D:** Concurrent use with vitamin D or its analogs can enhance calcium absorption and increase the risk of hypercalcemia.
### Monitoring
* **Serum Calcium:** Monitor regularly, especially during dose titration and in patients with risk factors for hypercalcemia. Aim to keep serum calcium within the target range for CKD patients (often 8.4-9.5 mg/dL, but local protocols may vary).
* **Serum Phosphate:** Monitor regularly to assess efficacy and guide dosing.
* **Serum Magnesium and Albumin:** Monitor as needed to interpret calcium levels correctly.
* **Intact PTH:** Monitor as part of bone mineral metabolism assessment in CKD patients.
### Clinical Pearls
* Administer calcium acetate with meals to maximize its phosphate-binding capacity.
* Educate patients about the signs and symptoms of hypercalcemia (e.g., constipation, nausea, increased urination, confusion, bone pain).
* Consider the total elemental calcium load from all sources (diet, supplements, other medications) when managing patients on calcium-based phosphate binders.
* In patients with hypophosphatemia, reduction or discontinuation of calcium acetate may be necessary.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions. Dosing and monitoring parameters may vary based on individual patient factors and local institutional protocols.
